|
|
| About MolecularMD |
|
|
|
| (1) What credentials does MolecularMD have? |
Molecular MD is certified and accredited by Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP).
As a CML ALLIANCE™ partner, MolecularMD has undergone a rigorous evaluation process and is one of only two laboratories Novartis has validated to perform QRT-PCR BCR-ABL testing.
|
| (2) Who are the scientific/clinical directors at MolecularMD? |
The scientific founders of MolecularMD are:
• Brian Druker, M.D.
• Michael Heinrich, M.D.
• Chad Galderisi, D.O. - Also MolecularMD Laboratory Director
Read more about our founders
Our scientific director is Emmanuel Beillard, Pharm.D, Ph.D.
|
| (3) What tests does MolecularMD perform? |
MolecularMD currently performs the following tests:
•BCR-ABL Quantitation Assay
•BCR-ABL T315I Assay
•BCR-ABL Kinase Domain Sequencing
Read more about BCR-ABL Quantitation
Read more about BCR-ABL Mutation Analysis |
| (4) What are your hours of operation? |
Monday through Saturday, our hours are:
•9 a.m. – 8 p.m. Eastern Time
•6 a.m. – 5 p.m. Pacific Time
|
| (5) What experience does MolecularMD have with performing quantitative RNA-based diagnostics? |
| MolecularMD’s founding scientific team has more than 30 years of combined experience in clinical cancer research. They have developed highly sensitive and reliable molecular assays for leukemias, lymphomas and solid tumors for clinical trials and clinical use and can quickly develop and validate new molecular quantitation assays for any type of blood-born disease or solid tumors. |
